Updates On Biocon Biologics Bribery Case

Updates on Biocon Biologics Bribery Case

Biocon executive among 5 held in 'bribery' case

Medical Dialogues

CBI arrests Biocon Biologics' AVP over allegations of bribery

CBI Charge Sheet Against Joint Drug Controller, Biocon Biologics Execut

Medical Dialogues

Biocon Surges After The US FDA Issues A VAI Status To Its Biologics Unit In Bengaluru | CNBC TV18

The Big Pharma Biocon Bribery Case In 2 Minute!

Gravitas: Biocon executives charged with bribing regulators

WION

Decoding Biocon Biologics’ Growth Trajectory | Opportunity In Multi-Billion Dollar Biosimilar Space

Biocon Biologics Restructures Deal With SII | Nithya Balasubramanian Speaks On This & More

Biocon Biologics To Close Viatris Deal Soon, IPO Plan Likely In 12-24 Months

Reporter's Take | Biocon Biologics raises Rs 530 crore at steep $3 bn valuation

Kiran Mazumdar Shaw Shares Her Views On Biocon Biologics Acquiring Viatris Biosimilar's Business

Brands Wil Be Exclusive To Eris, Co Will Have Right To Commercialise These Brands: Biocon Biologics

Biocon Biologics is well-placed to take advantage of opportunities in the biosimilars space: CEO

CNBC International News

'Serum Keen To Have Stake In Biocon Biologics,' Kiran Mazumdar-Shaw On ET Now

US Biosecure Act Provides A Big Opportunity To Indian Pharma Industry: Biocon & Biocon Biologics

Biocon Biologics: Strong Earnings In Q2, What's Expansion & Capex Utilisation Plans?; Shreehas Tambe

Biocon Biologics's Shreehas Tambe Speaks On US FDA's Observation | Bazaar Open Exchange | CNBC-TV18

Exclusive | Biocon Biologics Q4: Serum Will Double Investment To $300 Mn

Biocon Biologics Q2 Results: Earnings | Key growth Drivers For Upcoming QTR | Shreehas Tambe